Cortisol, 11β-Hydroxysteroid Dehydrogenases, and Hypertension

Hypersecretion of cortisol is associated with hypertension. In addition, an abnormal cortisol metabolism may play a role in the pathogenesis of hypertension. The 11β-hydroxysteroid dehydrogenase (11β-HSD) isozymes catalyze interconversion of cortisol and cortisone and play an important role in the regulation of the effects of cortisol. Activity of 11β-HSD type 2, converting active cortisol in inactive cortisone, is crucial in preventing access of cortisol to the renal mineralocorticoid receptors (MRs). Decreased activity of this isozyme in the kidney, either congenitally in Apparent Mineralocorticoid Excess syndrome or acquired following licorice consumption, allows cortisol access to the MRs, resulting in hypokalemic hypertension. In normotensive subjects, an association has been demonstrated between blood pressure increase on a high-salt diet and a mild decrease of renal 11β-HSD2 activity. In ectopic adrenocorticotropic hormone (ACTH), plasma cortisol levels are very high, resulting in mineralocorticoid hypertension caused by saturation of the available renal 11β-HSD2 capacity. Activity of the 11β-HSDs has also been demonstrated in many extrarenal sites. Several studies have demonstrated extrarenal effects of cortisol on blood pressure, as well as a possible role for altered extrarenal 11β-HSD activities in the pathogenesis of hypertension. More studies are needed to clarify the role of 11β-HSDs in the pathogenesis of hypertension.

Cortisol - 11β-hydroxysteroid dehydrogenases - hypertension - licorice

REFERENCES

• 1 Danese R D, Aron D C. Cushing's syndrome and hypertension.  Endocrinol Metab Clin North Am. 1994;  23 299-324
• 2 Fallo F, Paoletta A, Tona F et al.. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome.  J Intern Med. 1993;  234 595-598
• 3 Connell J M, Whitworth J A, Davies D L et al.. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man.  J Hypertens. 1987;  5 425-433
• 4 Vermeulen A, van der Straeten M. Adrenal cortical function in benign essential hypertension.  J Clin Endocrinol Metab. 1963;  23 574-578
• 5 Filipovsky J, Ducimetiere P, Eschwege E et al.. The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men.  J Hypertens. 1996;  14 229-235
• 6 Whitworth J A, Gordon D, McLachlan Troup N et al.. Dexamethasone suppression in essential hypertension: effects on cortisol and blood pressure.  Clin Exp Hypertens A. 1989;  11 323-335
• 7 Lakshmi V, Monder C. Evidence for independent 11-oxidase and 11-reductase activities of 11 beta-hydroxysteroid dehydrogenase: enzyme latency, phase transitions, and lipid requirements.  Endocrinology. 1985;  116 552-560
• 8 Monder C, White P C. 11 beta-hydroxysteroid dehydrogenase.  Vitam Horm. 1993;  47 187-271
• 9 Walker B R, Campbell J C, Williams B C et al.. Tissue-specific distribution of the NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase.  Endocrinology. 1992;  131 970-972
• 10 Whorwood C B, Mason J I, Ricketts M L et al.. Detection of human 11 beta-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts.  Mol Cell Endocrinol. 1995;  110 R7-12
• 11 Stewart P M, Murry B A, Mason J I. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform.  J Clin Endocrinol Metab. 1994;  79 480-484
• 12 Agarwal A K, Tusie-Luna M T, Monder C et al.. Expression of 11 beta-hydroxysteroid dehydrogenase using recombinant vaccinia virus.  Mol Endocrinol. 1990;  4 1827-1832
• 13 Brown R W, Chapman K E, Kotelevtsev Y et al.. Cloning and production of antisera to human placental 11beta-hydroxysteroid dehydrogenase type 2.  Biochem J. 1996;  313 1007-1017
• 14 Smith R E, Maguire J A, Stein Oakley A N et al.. Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues.  J Clin Endocrinol Metab. 1996;  81 3244-3248
• 15 Arriza J L, Weinberger C, Cerelli G et al.. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.  Science. 1987;  237 268-275
• 16 Palermo M, Shackleton C H, Mantero F et al.. Urinary free cortisone and the assessment of 11 beta- hydroxysteroid dehydrogenase activity in man.  Clin Endocrinol (Oxf). 1996;  45 605-611
• 17 Ulick S, Levine L S, Gunczler P et al.. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol.  J Clin Endocrinol Metab. 1979;  49 757-764
• 18 New M I, Levine L S, Biglieri E G et al.. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension.  J Clin Endocrinol Metab. 1977;  44 924-933
• 19 Quinkler M, Stewart P M. Hypertension and the cortisol-cortisone shuttle.  J Clin Endocrinol Metab. 2003;  88 2384-2392
• 20 Milford D V, Shackleton C H, Stewart P M. Mineralocorticoid hypertension and congenital deficiency of 11 beta-hydroxysteroid dehydrogenase in a family with the syndrome of ‘apparent’ mineralocorticoid excess.  Clin Endocrinol (Oxf). 1995;  43 241-246
• 21 Stewart P M, Corrie J E, Shackleton C H et al.. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.  J Clin Invest. 1988;  82 340-349
• 22 Stewart P M, Wallace A M, Valentino R et al.. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age.  Lancet. 1987;  2 821-824
• 23 MacKenzie M A, Hoefnagels W HL, Jansen R WMM et al.. The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy young volunteers.  J Clin Endocrinol Metab. 1990;  70 1637-1643
• 24 Stormer F C, Reistad R, Alexander J. Glycyrrhizic acid in liquorice-evaluation of health hazard.  Food Chem Toxicol. 1993;  31 303-312
• 25 Walker B R, Campbell J C, Fraser R et al.. Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome.  Clin Endocrinol. 1992;  37 483-492
• 26 Diederich S, Quinkler M, Miller K et al.. Human kidney 11 beta-hydroxysteroid dehydrogenase: regulation by adrenocorticotropin?.  Eur J Endocrinol. 1996;  134 301-307
• 27 van Uum S H, Houben A J, Hermus A R et al.. Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals.  J Hypertens. 2002;  20 2275-2283
• 28 Whitworth J A, Stewart P M, Burt D et al.. The kidney is the major site of cortisone production in man.  Clin Endocrinol (Oxf). 1989;  31 355-361
• 29 Riddle M C, McDaniel P A. Renal 11 beta-hydroxysteroid dehydrogenase activity is enhanced by ramipril and captopril.  J Clin Endocrinol Metab. 1994;  78 830-834
• 30 Burnier M, Roch-Ramel F, Brunner H R. Renal effects of angiotensin II receptor blockade in normotensive subjects.  Kidney Int. 1996;  49 1787-1790
• 31 Kerstens M N, Buter H, Navis G J et al.. 11beta-hydroxysteroid dehydrogenase activity in proteinuric patients and the effect of angiotensin-II receptor blockade.  Eur J Clin Invest. 2002;  32 513-518
• 32 Soro A, Ingram M C, Tonolo G et al.. Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension.  Hypertension. 1995;  25 67-70
• 33 Takeda Y, Miyamori I, Iki K et al.. Endogenous renal 11 beta-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension.  Hypertension. 1996;  27 197-201
• 34 Iki K, Miyamori I, Hatakeyama H et al.. The activities of 5 beta-reductase and 11 beta-hydroxysteroid dehydrogenase in essential hypertension.  Steroids. 1994;  59 656-660
• 35 van Uum S H, Walker B R, Hermus A R et al.. Effect of glycyrrhetinic acid on 11 beta-hydroxysteroid dehydrogenase activity in normotensive and hypertensive subjects.  Clin Sci (Lond). 2002;  102 203-211
• 36 Walker B R, Stewart P M, Shackleton C H et al.. Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension.  Clin Endocrinol. 1993;  39 221-227
• 37 Walker B R, Phillips D I, Noon J P et al.. Increased glucocorticoid activity in men with cardiovascular risk factors.  Hypertension. 1998;  31 891-895
• 38 Sigurjonsdottir H A, Franzson L, Manhem K et al.. Liquorice-induced rise in blood pressure: a linear dose-response relationship.  J Hum Hypertens. 2001;  15 549-552
• 39 Sigurjonsdottir H A, Manhem K, Axelson M et al.. Subjects with essential hypertension are more sensitive to the inhibition of 11 beta-HSD by liquorice.  J Hum Hypertens. 2003;  17 125-131
• 40 Lovati E, Ferrari P, Dick B et al.. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2.  J Clin Endocrinol Metab. 1999;  84 3745-3749
• 41 Ferrari P, Sansonnens A, Dick B et al.. In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice.  Hypertension. 2001;  38 1330-1336
• 42 Kerstens M N, van der Kleij F G, Boonstra A H et al.. Salt loading affects cortisol metabolism in normotensive subjects: relationships with salt sensitivity.  J Clin Endocrinol Metab. 2003;  88 4180-4185
• 43 Kornel L, Ramsay C, Kanamarlapudi N et al.. Evidence for the presence in arterial walls of intracellular- molecular mechanism for action of mineralocorticoids.  Clin Exp Hypertens A. 1982;  4 1561-1582
• 44 Ullian M E. The role of corticosteroids in the regulation of vascular tone.  Cardiovasc Res. 1999;  41 55-64
• 45 Kalsner S. Mechanism of hydrocortisone potentiation of responses to epinephrine and norepinephrine in rabbit aorta.  Circ Res. 1969;  24 383-395
• 46 Besse J C, Bass A D. Potentiation by hydrocortisone of responses to catecholamines in vascular smooth muscle.  J Pharmacol Exp Ther. 1966;  154 224-238
• 47 Beilin L J, Wade D N, Honour A J et al.. Vascular hyper-reactivity with sodium loading and with desoxycorticosterone induced hypertension in the rat.  Clin Sci. 1970;  39 793-810
• 48 Angelo Khattar M M, Thulesius O. Vascular effects of glucocorticosteroids, with special reference to budesonide.  Gen Pharmacol. 1983;  14 125-127
• 49 Berecek K H, Bohr D F. Whole body vascular reactivity during the development of deoxycorticosterone acetate hypertension in the pig.  Circ Res. 1978;  42 764-771
• 50 Grunfeld J P, Eloy L. Glucocorticoids modulate vascular reactivity in the rat.  Hypertension. 1987;  10 608-618
• 51 Sudhir K, Jennings G L, Esler M D et al.. Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function.  Hypertension. 1989;  13 416-421
• 52 Mangos G J, Walker B R, Kelly J J et al.. Cortisol inhibits cholinergic vasodilation in the human forearm.  Am J Hypertens. 2000;  13 1155-1160
• 53 Pirpiris M, Sudhir K, Yeung S et al.. Pressor responsiveness in corticosteroid-induced hypertension in humans.  Hypertension. 1992;  19 567-574
• 54 Walker B R, Yau J L, Brett L P et al.. 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids.  Endocrinology. 1991;  129 3305-3312
• 55 Walker B R, Connacher A A, Webb D J et al.. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man.  Clin Sci Colch. 1992;  83 171-178
• 56 Jamieson P M, Chapman K E, Edwards C R et al.. 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations.  Endocrinology. 1995;  136 4754-4761
• 57 Seckl J R, Walker B R. Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action.  Endocrinology. 2001;  142 1371-1376
• 58 Smith R E, Little P J, Maguire J A et al.. Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme.  Clin Exp Pharmacol Physiol. 1996;  23 549-551
• 59 Hadoke P W, Christy C, Kotelevtsev Y V et al.. Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase.  Circulation. 2001;  104 2832-2837
• 60 Christy C, Hadoke P W, Paterson J M et al.. 11beta-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids.  Hypertension. 2003;  42 580-587
• 61 Reul J M, de Kloet E R. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation.  Endocrinology. 1985;  117 2505-2511
• 62 Roland B L, Li K X, Funder J W. Hybridization histochemical localization of 11 beta-hydroxysteroid dehydrogenase type 2 in rat brain.  Endocrinology. 1995;  136 4697-4700
• 63 Gomez-Sanchez E P, Fort C M, Gomez-Sanchez C E. Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension.  Am J Physiol. 1990;  258 E482-E484
• 64 Barker D J, Bull A R, Osmond C et al.. Fetal and placental size and risk of hypertension in adult life.  BMJ. 1990;  301 259-262
• 65 Huxley R R, Shiell A W, Law C M. The role of size at birth and postnatal catch-up growth in determining systolic blood pressure: a systematic review of the literature.  J Hypertens. 2000;  18 815-831
• 66 Reinisch J M, Simon N G, Karow W G et al.. Prenatal exposure to prednisone in humans and animals retards intrauterine growth.  Science. 1978;  202 436-438
• 67 Benediktsson R, Lindsay R S, Noble J et al.. Glucocorticoid exposure in utero: new model for adult hypertension.  Lancet. 1993;  341 339-341
• 68 Lindsay R S, Lindsay R M, Waddell B J et al.. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone.  Diabetologia. 1996;  39 1299-1305
• 69 Stewart P M, Rogerson F M, Mason J I. Type 2 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis.  J Clin Endocrinol Metab. 1995;  80 885-890
• 70 Strandberg T E, Jarvenpaa A L, Vanhanen H et al.. Birth outcome in relation to licorice consumption during pregnancy.  Am J Epidemiol. 2001;  153 1085-1088